Divergence of P53, PTEN, PI3K, Akt and mTOR expression in tonsillar cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0347|37|5|636-643

ISSN： 1043-3074

Source： HEAD & NECK: JOURNAL FOR THE SCIENCES & SPECIALTIES OF THE HEAD AND NECK, Vol.37, Iss.5, 2015-05, pp. : 636-643

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Significance of Genetic Variations in the PI3K/PTEN/AKT/mTOR Pathway in Korean Patients with Colorectal Cancer

By  

Oncology, Vol. 79, Iss. 3-4, 2011-03 ,pp. : 278-282

Karger

Access to resources Recommend Favorite

Signaling Intermediates (PI3K/PTEN/AKT/mTOR and RAF/MEK/ERK Pathways) as Therapeutic Targets for Anti-Cancer and Anti-Angiogenesis Treatments

By  

Current Signal Transduction Therapy, Vol. 4, Iss. 2, 2009-05 ,pp. : 130-143

Bentham Science Publishers

Access to resources Recommend Favorite

PI3K/PTEN/AKT/mTOR polymorphisms: Association with clinical outcome in patients with head and neck squamous cell carcinoma receiving cetuximab‐docetaxel

By  

HEAD & NECK: JOURNAL FOR THE SCIENCES & SPECIALTIES OF THE HEAD AND NECK, Vol. 37, Iss. 4, 2015-04 ,pp. : 471-478

John Wiley & Sons Inc

Access to resources Recommend Favorite

GOLM1 promotes prostate cancer progression through activating PI3K‐AKT‐mTOR signaling

By  

THE PROSTATE, Vol. 78, Iss. 3, 2018-02 ,pp. : 166-177

John Wiley & Sons Inc

Access to resources Recommend Favorite

The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross‐talk, and therapies

By  

ORAL DISEASES, Vol. 21, Iss. 7, 2015-10 ,pp. : 815-825

John Wiley & Sons Inc

Access to resources Recommend Favorite